Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587602 | 0.89 | TNNC1 (0.38) | — | |
| SCHEMBL8975003 | 0.88 | NFE2L2 (0.46) | NFE2L2LOXL2GRIK1GRIK2HSD11B1 | |
| SCHEMBL4772823 | 0.80 | NFE2L2 (0.43) | NFE2L2GRIK1GRIK2HSD11B1APP | |
| SCHEMBL4772837 | 0.80 | NFE2L2 (0.43) | NFE2L2GRIK1GRIK2HSD11B1APP | |
| SCHEMBL15050819 | 0.80 | NFE2L2 (0.47) | NFE2L2HSD11B1APPPTGS1 | |
| SCHEMBL11353943 | 0.80 | KCNH2 (0.42) | NFE2L2GRIK1GRIK2TAAR1FBP1 | |
| SCHEMBL1830641 | 0.80 | HSD11B1 (0.44) | NFE2L2GRIK1GRIK2HSD11B1APP | |
| SCHEMBL15050816 | 0.80 | NFE2L2 (0.47) | NFE2L2HSD11B1APPPTGS1 | |
| SCHEMBL1829428 | 0.79 | IDO1 (0.50) | — | |
| SCHEMBL1323652 | 0.79 | IDO1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691803-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | Warner-Lambert Company LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056004-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | NFE2L2 1798/4885LOXL2 1820/4885GRIK1 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.